Celecoxib Japan Observational Study for the Patients With Acute Pain

Astellas Pharma Inc784 enrolled

Overview

This study is to assess the safety and efficacy of celecoxib on the pain relief from acute pain.

Patients with traumatic pain, post-surgical and tooth extract pain will be included in this study. Patients will receive Celecoxib for 2 weeks and the efficacy on pain relief and the safety will be evaluated.

Study Type

OBSERVATIONAL

Enrollment

784

Conditions

Patients With Traumatic Pain, Post-surgical Pain and Tooth Extract Pain

Interventions

CelecoxibDRUG

oral

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with traumatic pain, post-surgical pain and tooth extract pain Exclusion Criteria: * Hyperreactive to sulfonamide * Aspirin asthma patients * Peptidic ulcer patients * Serious liver disease patients * Serious kidney disease patients * Serious heart failure patients * End of pregnancy

Locations (7)

Unnamed facility

Chūbu, Japan

Unnamed facility

Hokkaido, Japan

Unnamed facility

Kansai, Japan

Unnamed facility

Kantou, Japan

Unnamed facility

Kyushu, Japan

Outcomes

Primary Outcomes

Safety assessed by the incidence of adverse events and lab-tests

Time frame: For 2 weeks

Secondary Outcomes

Overall pain improvement assessed by visual analogue scale (VAS)

Time frame: Baseline and week-2

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.